Cite
APA Citation
Coates, L. C., Mease, P. J., Gladman, D. D., Navarra, S., Bao, W., & Gaillez, C. (2023). secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD open, 9(2), . http://access.bl.uk/ark:/81055/vdc_100185082817.0x000008